$MO

McQUADE KATHRYN B. purchased $101K of MO

McQUADE KATHRYN B. purchased 1,500 shares of ALTRIA GROUP, INC. (MO) at $67.62 ($0.10M total) on 2026-09-09.

Original reporting
SEC EDGAR · McQUADE KATHRYN B.
Published Sep 11, 2026, 6:32 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 11, 2026, 6:41 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$MO
Neutral
medium confidence
Mentioned
$MO
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$MONeutralLow
01

Why it matters

The director's purchase adds a small amount to her stake, indicating personal confidence but unlikely to move the stock.

02

Market read

Limited relevance; primarily of interest to insiders and institutional investors monitoring director holdings.

03

What to watch

Potential upcoming regulatory or litigation risks for Altria that may temper any positive sentiment from insider buying.

Relevance 5/10Novelty 4/10Timing: filed today

Background

Altria Group (MO) is a major U.S. tobacco company. Insider transactions are regularly disclosed via Form 4 filings.

Company-level read

Ticker impact

$MONeutralMedium confidence
Context

Director Kathryn B. McQuade purchased 1,500 shares of Altria Group for $101,430, increasing her holdings to 114,929 shares.

Expected impact

Minimal short-term price effect; may provide slight upside bias.

Evidence & confidence

The purchase amount ($101k) is modest for a large-cap company; market impact is likely limited.

Market effects

None significant; insider activity does not affect the broader tobacco sector.

U.S. market only; no regional ripple.

Low; limited to Altria investors.

Counterpoint

The purchase could be a routine portfolio rebalancing rather than a strong bullish signal.

Key entities

  • Altria Group, Inc.

    U.S. tobacco manufacturer (ticker MO).

  • Kathryn B. McQuade

    Director of Altria Group.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$MOMed

Trump administration plans to speed approvals of vapes and nicotine pouches - WSJ

The Trump administration plans to speed up approvals for smoke-free nicotine products like vapes and nicotine pouches, easing FDA review requirements. This benefits tobacco companies such as Altria (MO), Philip Morris (PM), and British American Tobacco (BTI), which face regulatory delays. The move aims to reduce illegal products but faces opposition from health advocates concerned about youth access.

$MOMed

Yielding Dividend Stock That's Beating the Market in 2026

Altria Group (MO) reported 24% total returns in 2026, outpacing the S&P 500's 14%. Shares fell after Q2 earnings missed estimates, with revenue at $5.35B and EPS at $1.37. The company faces long-term risks due to declining cigarette use and competition in smokeless products. Altria trades at 12x forward earnings with a 6.4% yield, but its strategy to sustain growth remains uncertain.

$MOMed

Altria Units Sue FDA Over PMTA Rule, Spotlighting Review Delays

Altria Group (MO) subsidiaries Helix Innovations and NJOY sued the FDA over its 2021 PMTA rule, arguing it violates the Tobacco Control Act's 180-day review deadline. The lawsuit claims FDA delays begin with Acceptance and Filing Reviews. FDA has reduced its backlog but Altria seeks a court order to vacate the rule. MO stock traded between $54.70 and $77.06 over the past year, closing at $69.56 on Wednesday.